LMT-28 is a IL-6 blocker. It acts by targeting the IL-6 receptor. References: Armstead WM, Hekierski H, Pastor P, Yarovoi S, Higazi AA, Cines DB. Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK. Transl Stroke Res. 2018 Feb 23. doi: 10.1007/s12975-018-0617-z. [Epub ahead of print] PubMed PMID: 29476447.

纯度：≥98%

CAS：1239600-18-0